(The above is a vision of what a fully integrated AI-driven multiomics health system might look like)
Genomics England has committed to upping the use of 'multiomics' for research and potentially clinical practice. A commitment reiterated by Sue Hill at this year's Festival of Genomics and reflected in the recent announcement by Illumina that it is expanding its offer to include proteomics.
AI can help identify new associations and discover patterns in the data invisible to the naked eye. And it can effectively reduce the 'noise' in the data, maybe pointing to clinically actionable signals. But extracting clinically relevant insights from multiomic data is a significant challenge when using traditional statistical methods.
We recently convened a multidisciplinary group of clinicians, researchers, academics, policy makers and industry professionals to find out where they are using - or expect to use -AI-driven multiomics, and where the barriers to uptake lie.
Read what we found: AI-driven multiomics in health: our 2025 roundtable insights
To find out how we can help you better understand the views of your health stakeholders, contact us: intelligence@phgfoundation.org
